Canakinumab

證據等級: L5

預測適應症: 10 個

Canakinumab: From Cryopyrin-Associated Periodic Syndromes to Familial Mediterranean Fever

One-Sentence Summary

Canakinumab (Ilaris) is a fully human anti-IL-1β monoclonal antibody globally approved for Cryopyrin-Associated Periodic Syndromes (CAPS) and several related autoinflammatory conditions, but currently not marketed in Taiwan. While TxGNN's top-ranked prediction is hepatic infarction (Rank #1, L5, no clinical evidence), the most actionable prediction in this analysis is Familial Mediterranean Fever, Autosomal Dominant (Rank #6), supported by 7 clinical trials (including 5 completed Phase 3 studies) and 20 publications — among them the landmark Phase 3 CLUSTER trial published in the New England Journal of Medicine.

Quick Overview

Item	Content
Original Indication	CAPS (not licensed in Taiwan; globally approved for CAPS, FMF, TRAPS, HIDS/MKD, sJIA)
Predicted New Indication (Actionable)	Familial Mediterranean Fever, Autosomal Dominant
TxGNN Prediction Score	99.41% (Rank #6 among analyzed indications; Rank #1 hepatic infarction has no supporting clinical evidence)
Evidence Level	L1
Taiwan Market Status	✗ Not marketed (0 authorizations)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Although formal MOA documentation is listed as a data gap in this Evidence Pack, published literature consistently describes Canakinumab's mechanism: it is a fully human IgG1 monoclonal antibody that selectively binds and neutralizes free IL-1β with high affinity. By preventing IL-1β from engaging the IL-1 receptor, it blocks downstream NF-κB signaling and the production of prostaglandins, acute-phase reactants (CRP, SAA), and secondary inflammatory mediators. This mechanism of action was first described in its 2009 FDA approval for CAPS and has been replicated across multiple disease settings.

Familial Mediterranean Fever (FMF) is caused by gain-of-function mutations in the MEFV gene encoding pyrin, a key regulator of the pyrin inflammasome. Mutant pyrin leads to uncontrolled inflammasome activation → excess caspase-1 cleavage → uncontrolled IL-1β secretion → recurrent acute sterile serositis (peritonitis, pleuritis, arthritis) and fever attacks lasting 12–72 hours. The mechanistic bridge to Canakinumab is therefore direct: neutralizing IL-1β eliminates the central inflammatory mediator responsible for FMF attacks.

CAPS (the original approved indication) and FMF share the same terminal effector pathway — IL-1β overproduction from inflammasome dysregulation — with the difference lying only in the upstream mutant gene (NLRP3 in CAPS vs. MEFV in FMF). This shared biology makes the TxGNN prediction biologically sound rather than incidental, and it is independently validated by regulatory approval: the FDA approved Canakinumab for colchicine-resistant FMF in 2016 on the strength of the Phase 3 CLUSTER trial.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00685373	Phase 3	Completed	166	Largest Phase 3 long-term safety and efficacy database for canakinumab in CAPS (FCAS, MWS, NOMID); enrolled patients from prior studies plus newly identified patients; ≥6 months treatment
NCT00465985	Phase 3	Completed	35	Three-part trial with double-blind, placebo-controlled withdrawal design (Part II) in Muckle-Wells Syndrome; confirmed durable efficacy and identified responders for long-term therapy
NCT01302860	Phase 3	Completed	17	1-year open-label multicenter trial in CAPS patients aged ≤4 years; assessed efficacy, tolerability, and compatibility with childhood vaccination schedules
NCT01576367	Phase 3	Completed	17	Open-label extension of NCT01302860; generated long-term safety and tolerability data for young CAPS patients continuing from the parent study
NCT00991146	Phase 3	Completed	19	Open-label efficacy and safety study in Japanese CAPS patients (FCAS, MWS, NOMID); 6-month core treatment with extension until Japan market approval in 2012
NCT01242813	Phase 2	Completed	20	Open-label 4-month canakinumab treatment plus 6-month drug-free follow-up in TRAPS patients; established dosing strategy and efficacy signals in related periodic fever syndromes
NCT06838143	Observational	Recruiting	25	REASSURE study (2025–2028): non-interventional real-world safety and effectiveness of Ilaris 150 mg in CAPS, crFMF, TRAPS, HIDS/MKD, and sJIA in routine clinical practice

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29768139	2018	Phase 3 RCT (CLUSTER)	N Engl J Med	Pivotal CLUSTER trial: canakinumab significantly reduced attack rates across FMF, TRAPS, and HIDS/MKD vs. placebo; formed the primary basis for FDA/EMA approval in these indications
35874710	2022	Systematic Review	Front Immunol	First systematic review covering all approved IL-1 blockers; confirmed canakinumab's efficacy and manageable safety profile across the full spectrum of autoinflammatory disorders
37769252	2024	Systematic Review & Meta-analysis	Rheumatology (Oxford)	Quantified efficacy and safety of anti-IL-1 agents specifically in FMF across multiple international cohorts; strongly supported use in colchicine-resistant patients
40040547	2025	Cohort Study	Int J Rheum Dis	Compared canakinumab with and without concomitant colchicine in FMF; characterized effects on attack frequency, CRP/SAA levels, and renal outcomes
34568239	2021	Retrospective Cohort	Front Pediatr	65 colchicine-resistant pediatric FMF patients: complete remission achieved with monthly canakinumab dosing; dose tapering successfully implemented in sustained responders
36961326	2023	Cohort Study	Rheumatology (Oxford)	Established a treatment tapering and discontinuation protocol for canakinumab in pediatric colchicine-resistant FMF; critical for long-term management decisions
31463794	2019	Retrospective Analysis	Paediatric Drugs	Single-center experience with canakinumab in pediatric FMF patients; documented clinical and laboratory responses in children unresponsive to colchicine
28362189	2017	Clinical Review	Expert Rev Clin Immunol	Comprehensive evidence review for canakinumab in FMF; summarized key clinical trials and discussed positioning relative to other anti-IL-1 agents
36062765	2022	Review	Clin Exp Rheumatol	Compared clinical outcomes of IL-1 inhibition in FMF; discussed treatment expectations, colchicine combination strategies, and long-term remission data
32806879	2020	Review	Turk J Med Sci	Contemporary pathogenesis-to-treatment review of FMF; contextualized IL-1 blockade within modern management guidelines and MEFV mutation spectrum

Taiwan Market Information

Canakinumab currently has no marketing authorizations in Taiwan (0 licenses; market status: not marketed as of 2026-04-20).

The drug is marketed internationally under the brand name Ilaris (Novartis) with the following globally approved indications for reference:

Region	Approved Indications
FDA (USA)	CAPS (FCAS, MWS, NOMID), FMF (colchicine-resistant), TRAPS, HIDS/MKD, sJIA, Adult-onset Still's disease
EMA (Europe)	CAPS, FMF (colchicine-resistant or intolerant), TRAPS, HIDS/MKD, sJIA

Any use in Taiwan would require a full NDA submission to the TFDA, including bridging clinical data for the relevant patient population if required.

Safety Considerations

Please refer to the package insert for safety information.

Important note: Taiwan-specific package insert data (warnings and contraindications) was not available in this Evidence Pack and is classified as a blocking data gap — it must be obtained from the EMA/FDA label or Novartis before any formal safety evaluation. No drug-drug interaction records were identified in the DDI database query. Given canakinumab's class as an immunomodulatory biologic, known class-level concerns include serious infections (including opportunistic infections and tuberculosis reactivation) and potential interference with vaccines.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Canakinumab's mechanism of action precisely targets the pathophysiological effector of FMF — the IL-1β overflow downstream of mutant pyrin inflammasome hyperactivation. This is not speculative repurposing: the drug holds active FDA and EMA approvals for FMF, backed by a Phase 3 RCT published in the New England Journal of Medicine. The Taiwan opportunity is best characterized as a market access gap rather than an unproven repurposing hypothesis.

To proceed, the following is needed:

Obtain the TFDA package insert (or EMA/FDA label as proxy) to resolve the blocking safety data gap before regulatory submission planning
Secure formal MOA documentation from DrugBank or the prescribing information for dossier completeness
Conduct a Taiwan FMF patient population estimate — FMF is a rare disease with ethnic clustering (Mediterranean/Middle Eastern heritage); estimate local disease burden to support orphan drug pathway feasibility
Perform a health economic assessment: as a subcutaneous biologic with high unit cost, canakinumab will require rare disease pricing justification and potential NHI reimbursement negotiation
Review pediatric dosing data in the Taiwan context (age cutoffs for sJIA vs. periodic fever indications differ)
Design a safety monitoring plan covering infection surveillance, TB screening (prior to initiation), and long-term immunosuppression follow-up consistent with biologic therapy standards
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.